Navigation Links
Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day Through On-line Awareness Effort
Date:8/11/2009

BROOMFIELD, Colo., Aug. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today the launch of its "Lost & Found" campaign, an on-line initiative whereby each visit to www.lostandfoundcampaign.com prompts a $1 donation by Accera to support the Alzheimer's Foundation of America (AFA).

Every AD patient, caregiver or family who visits the "Lost & Found" Web site may participate in this fundraising campaign by simply selecting an icon that represents something they have lost or forgotten that day. Clicking on an icon will trigger a donation from Accera to AFA at no cost to the individual participants. All funds generated throughout this initiative will be donated to AFA on November 17, 2009, "National Memory Screening Day," to further AFA's efforts to support individuals with Alzheimer's disease and their families. The Web site also contains information on current treatment therapies and educational links for patients and caregivers.

National Memory Screening Day, an annual initiative sponsored by AFA, provides free, confidential memory screenings to individuals concerned about memory loss with the objective of early detection and intervention. Qualified healthcare professionals offer the face-to-face screenings at convenient locations in communities across the nation.

"We are pleased to be the recipients of Accera's 'Lost & Found' campaign as we work to raise awareness about National Memory Screening Day," said Eric J. Hall, AFA's president and chief executive officer. "With the incidence of Alzheimer's disease escalating, AFA is extremely appreciative of those who understand the vital need for support services and the difference they can make for individuals with dementia and their families."

Steve Orndorff, Ph.D., President and CEO of Accera, Inc., stated, "Our goal through this effort is to signal to patients and caregivers that there are many people and companies, like Accera, dedicated to combating this devastating disease." He continued, "With the downturn of the economy, we wanted to enable individuals to make a contribution towards this effort without having to donate their own income. Through our initiative we hope to improve the quality of life for patients and caregivers."

"Lost & Found" submissions will be accepted on-line through November 13,

2009.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About the Alzheimer's Foundation of America (AFA)

The Alzheimer's Foundation of America (AFA) is a nonprofit organization based in New York City that focuses on providing optimal care to individuals with Alzheimer's disease and related illnesses, and their families, and unites more than 1,200 member organizations nationwide that provide hands-on programs and services to meet the educational, social, emotional and practical needs of those affected by the disease. AFA's services include a toll-free hot line with counseling by licensed social workers, a free caregiver magazine, professional training and its signature annual National Memory Screening Day. For information, call 866-AFA-8484 or visit www.alzfdn.org.

About Alzheimer's Disease

Alzheimer's disease, the most common form of dementia, is a progressive and fatal disease. In the United States, 5.2 million people are living with AD, and it has become the seventh leading cause of death. The disease attacks brain cells, resulting in loss of memory, executive function and language skills.

AD significantly impacts millions of family members and other caregivers - mentally, physically and financially. The National Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week. With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.

About Accera, Inc.

Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona. For more information about Accera, please visit www.accerapharma.com.

    Contacts:
    Accera, Inc.
    Steve Orndorff, Ph.D. President and CEO sorndorff@accerapharma.com

    Richard Lewis Communications, Inc.
    (212) 827-0020
    Andrew Mielach amielach@rlcinc.com
    Tamara Bright tbright@rlcinc.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
2. Accera, Inc. to Present at Upcoming Investor Conferences
3. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
4. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
5. Accera, Inc. Completes $35 Million Series C Financing
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
8. Zeus Expands International Support With New Hires
9. GenVec Expands Contract Supporting Malaria Vaccine Program
10. Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
11. NIH funds support UAB joint replacement research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016 On Thursday, February 11, ... for community, health and disaster services, and the ... to enhance care coordination and service delivery for the ... need and to better connect service providers to the ... San Diego has handled more than ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf ... today announced an interactive FDA compliance training course, Writing Effective ... Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones and ...
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
Breaking Biology Technology:
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):